The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem CellTransplantation Is an Independent PredictiveParameter

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages

  Korthals, Mark ^a,b   Sehnke, Nina ^a   Kronenwett, Ralf ^a   Bruns, Ingmar ^a   Mau, Jochen ^a   Zohren, Fabian ^a   Haas, Rainer ^a   Kobbe, Guido ^a   Fenk, Roland ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Minimal residual disease; Multiple myeloma; Prognostic parameter; RQ IgH PCR

Indexed keywords

ALPHA INTERFERON; BETA ACTIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CHROMOSOME ANALYSIS; DISEASE ASSOCIATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HIGH DOSE CHEMOTHERAPY; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METAPHASE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; WHOLE BODY RADIATION;

EID: 84856947756     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.002     Document Type: Article

References (27)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
2. Greipp P.R., San M.J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
3. Zhou Y., Nair B., Shaughnessy J.D., et al. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol 2009, 145:637-641.
4. O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006, 37:731-737.
5. Harousseau J.L., Avet-Loiseau H., Attal M., et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009, 27:5720-5726.
6. Glasmacher A., Hahn C., Hoffmann F., et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006, 132:584-593.
7. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med 2005, 352:2487-2498.
8. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. NEngl J Med 2007, 357:2123-2132.
9. Paiva B., Vidriales M.B., Cervero J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
10. Bakkus M.H., Bouko Y., Samson D., et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. BrJ Haematol 2004, 126:665-674.
11. Sarasquete M.E., Garcia-Sanz R., Gonzalez D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
12. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
13. Ladetto M., Pagliano G., Ferrero S., et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010, 28:2077-2084.
14. Szczepanski T., Orfao A., van der Valen V.H.J., San Miguel J.F., van Dongen J.J. Minimal residual disease in leukaemia patients. Lancet Oncol 2001, 2:409-417.
15. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
16. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
17. Fenk R., Ak M., Kobbe G., et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse inpatients with multiple myeloma. Haematologica 2004, 89:557-566.
18. Moreau P., Attal M., Pegourie B., et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2011, 117:3041-3044.
19. Moreau P., Misbahi R., Milpied N., et al. Long-term results (12years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002, 16:1838-1843.
20. Rajkumar S., Fonseca R., Lacy M., et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1999, 24:497-503.
21. Singhal S., Powles R., Sirohi B., Treleaven J., Kulkarni S., Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002, 30:673-679.
22. Paiva B., Martinez-Lopez J., Vidriales M.B., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011, 29:1627-1633.
23. Mead G.P., Carr-Smith H.D., Drayson M.T., Morgan G.J., Child J.A., Bradwell A.R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004, 126:348-354.
24. Billadeau D., Ahmann G., Greipp P., Van N.B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 1993, 178:1023-1031.
25. Kiel K., Cremer F.W., Rottenburger C., et al. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 23:1019-1027.
26. Matsui W., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336.
27. Rottenburger C., Kiel K., Bosing T., et al. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 1999, 106:545-552.